JW Pharmaceutical Corporation
001060 · KOSPI · Healthcare · ₩523.4B (approx. $392.5M)· Nat'l Pension stake 5.50% (2024-12-31)
₩23,000-0.7%vs prev closeclose of 2026-10-30 · not real-time
Valuation summary
Looks undervalued
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer.· Source: company profile (yfinance/Yahoo Finance)
💰 Net stock buybacks last fiscal year: ₩9.5B · 1.82% of market cap
Valuation summary68/100Downside rigidity42/100Upside potential34/100
Score summary
A summary of valuation factors — not a buy recommendation. You decide.
Data as of: 2026-10-30 · end-of-day, not real-timeData as of — price/valuation/technicals: the close date above · NPS stake: US=quarterly SEC 13F, Korea=annual · short interest: exchange's latest settlement · fundamentals: latest filing
Peers
| Company | PER | PBR | ROE | Div | Score |
|---|---|---|---|---|---|
| JW중외제약 | 5.6 | 1.3 | 28% | 2.8% | 36 |
| 파미셀 | 12.0 | 3.9 | -29% | 0.5% | 25 |
| 동아제약 | 6.8 | 0.5 | 7% | 2.0% | 37 |
| 신풍제약 | – | 1.6 | 0% | 0.0% | 22 |
| 보령 | 5.9 | 0.8 | 14% | 1.9% | 41 |
| 동아에스티 | 37.9 | 0.5 | 1% | 2.1% | 26 |
Same sector, nearest by market cap · – = no data (value traps excluded)
Price chart
View on Naver Finance →· Chart: Naver Finance
The chart (long-term trend, Ichimoku cloud) is for observation only — not a buy or sell signal.
Structure analysis · observation only
Shows only where the current price sits within the channel structure (based on past swings).
Position: 0.5~1.0 zone · Downtrend channelStructure as of 2026-10-30
Channel levels (price by multiple)
- Baseline (0)₩25,898
- ×0.5₩23,718
- Current price₩23,000
- ×1₩21,537
- ×1.5₩19,356
- ×2₩17,175
- ×2.5₩14,995
- ×3₩12,814
The channel, levels and gaps are observational geometry showing where the current price sits within past swing structure. They are not a rebound/bottom probability, a price target, or a buy/sell signal — plain chart patterns carry no reliable predictive edge (our backtest conclusion).
A highlight of the key metrics detailed below.
Undervalued vs sector 80/100 within Healthcare — higher means lower multiples (PER·PB·EV/EBITDA·PSR) than sector peers. Growth sectors carry higher multiples, so this is a same-sector relative view, not absolute cheapness (observational).
PER vs its own history PER is in the top 47% of its own 8-year range (historically expensive)Range 40–107.8 · median 63.6Observational only — a lower PER can reflect slowing growth, so 'cheap' isn't always undervalued.
Why it looks cheap
- P/E (Price/Earnings)5.6
- FCF Yield12.7%
- EV/EBITDA3.9
Why it might be risky
- –
Strategy ranks
Top-tier in 4 of 6 evaluated strategies
Ranks within the Korea market — tap to open that ranking (ranks are per market).
Valuation
- P/E (Price/Earnings)
- 5.6
- Forward P/E
- –
- P/B (Price/Book)
- 1.3
- PEG
- –
- P/S (Price/Sales)
- 0.6
- Dividend Yield
- 2.8%
- FCF Yield
- 12.7%
- EV/EBITDA
- 3.9
- EV/Sales
- 0.6
- Net Debt / EBITDA
- -0.24
- P/CF (Price/Cash Flow)
- 3.9
Quality & growth
- ROE (Return on Equity)
- 27.6%
- ROA (Return on Assets)
- 10.8%
- Rule of 40
- 31.2
- Earnings Growth
- –
Past returns
1M
-13.4%
3M
+4.5%
6M
-28.8%
1Y
+4.9%
3Y
-40.7%
5Y
-0.4%
Past returns — they do not guarantee future results.
Enterprise value
Market cap
₩523.4B
Enterprise value (EV)
₩496.1B
Net cash
₩30.3B
vs market cap
94.8%
EV as reported by our data provider (Yahoo Finance) · net debt is our own calc (total debt − cash) · definitions differ, so EV need not equal market cap + net debt (minority interest, preferred stock)
More indicators
Sortino
0.54
Downside vol
31.80%
Max drawdown (3y)
-49.54%
Moderate drop from peak
Volatility (annual.)
49.53%
Large price swings
RSI(14) daily
30.60
RSI(14) weekly
38.00
RSI(14) monthly
45.50
vs 200d MA
-18.23%
Below 200-day avg
Trend slope (annualized)
-4.93%
No clear trend
FCF margin
8.10%
Beta
1.02
Moves with market
Payout ratio
15.53%
Sustainable
Price/Graham
0.58
Undervalued
Buyback yield
1.82%
Golden cross
✕ not aligned
Color: green = healthy, red = caution (absolute thresholds, value/quality metrics only). Downside vol & Sortino are annualized. Max drawdown = largest drop from a 3-year peak; volatility = 1-year annualized. Price/Graham < 1 = below Graham fair value (profitable, positive-equity names only). RSI < 30 = oversold. For reference only.
Long-term trend (Ichimoku)
A Japanese trend tool. Price above the 'cloud' is supportive; below is weak. A strong uptrend doesn't mean it's cheap — stocks that have run up are usually more expensive.
D
Below the cloud (weak)
W
Below the cloud (weak)
M
Below the cloud (weak)